These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15310757)

  • 1. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome.
    Tanimoto Y; Yokozeki M; Hiura K; Matsumoto K; Nakanishi H; Matsumoto T; Marie PJ; Moriyama K
    J Biol Chem; 2004 Oct; 279(44):45926-34. PubMed ID: 15310757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts.
    Suzuki H; Suda N; Shiga M; Kobayashi Y; Nakamura M; Iseki S; Moriyama K
    J Cell Physiol; 2012 Sep; 227(9):3267-77. PubMed ID: 22105374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts.
    Mansukhani A; Bellosta P; Sahni M; Basilico C
    J Cell Biol; 2000 Jun; 149(6):1297-308. PubMed ID: 10851026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse model.
    Morita J; Nakamura M; Kobayashi Y; Deng CX; Funato N; Moriyama K
    Dev Dyn; 2014 Apr; 243(4):560-7. PubMed ID: 24259495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of the Apert canonical S252W FGFR2 mutation in a patient without severe syndactyly.
    Passos-Bueno MR; Richieri-Costa A; Sertié AL; Kneppers A
    J Med Genet; 1998 Aug; 35(8):677-9. PubMed ID: 9719378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis.
    Lemonnier J; Haÿ E; Delannoy P; Lomri A; Modrowski D; Caverzasio J; Marie PJ
    J Bone Miner Res; 2001 May; 16(5):832-45. PubMed ID: 11341328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis.
    Yokota M; Kobayashi Y; Morita J; Suzuki H; Hashimoto Y; Sasaki Y; Akiyoshi K; Moriyama K
    PLoS One; 2014; 9(7):e101693. PubMed ID: 25003957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The study of abnormal bone development in the Apert syndrome Fgfr2+/S252W mouse using a 3D hydrogel culture model.
    Yang F; Wang Y; Zhang Z; Hsu B; Jabs EW; Elisseeff JH
    Bone; 2008 Jul; 43(1):55-63. PubMed ID: 18407821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR2 mutation in a patient with Apert syndrome associated with humeroradial synostosis.
    Kanauchi Y; Muragaki Y; Ogino T; Takahara M; Tsuchida H; Ishigaki D
    Congenit Anom (Kyoto); 2003 Dec; 43(4):302-5. PubMed ID: 15041782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P253R fibroblast growth factor receptor-2 mutation induces RUNX2 transcript variants and calvarial osteoblast differentiation.
    Baroni T; Carinci P; Lilli C; Bellucci C; Aisa MC; Scapoli L; Volinia S; Carinci F; Pezzetti F; Calvitti M; Farina A; Conte C; Bodo M
    J Cell Physiol; 2005 Feb; 202(2):524-35. PubMed ID: 15389579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of FGFR Signaling on Cell Proliferation and Differentiation of Apert Dental Cells.
    Lu C; Huguley S; Cui C; Cabaniss LB; Waite PD; Sarver DM; Mamaeva OA; MacDougall M
    Cells Tissues Organs; 2016; 201(1):26-37. PubMed ID: 26613250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrantly activated Wnt/β-catenin pathway co-receptors LRP5 and LRP6 regulate osteoblast differentiation in the developing coronal sutures of an Apert syndrome (Fgfr2
    Min Swe NM; Kobayashi Y; Kamimoto H; Moriyama K
    Dev Dyn; 2021 Mar; 250(3):465-476. PubMed ID: 32822074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dura in the pathogenesis of syndromic craniosynostosis: fibroblast growth factor receptor 2 mutations in dural cells promote osteogenic proliferation and differentiation of osteoblasts.
    Ang BU; Spivak RM; Nah HD; Kirschner RE
    J Craniofac Surg; 2010 Mar; 21(2):462-7. PubMed ID: 20489451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses.
    Passos-Bueno MR; Sertié AL; Richieri-Costa A; Alonso LG; Zatz M; Alonso N; Brunoni D; Ribeiro SF
    Am J Med Genet; 1998 Jul; 78(3):237-41. PubMed ID: 9677057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosome-mediated small interfering RNA delivery inhibits aberrant osteoblast differentiation in Apert syndrome model mice.
    Myo AC; Kobayashi Y; Niki Y; Kamimoto H; Moriyama K
    Arch Oral Biol; 2023 Sep; 153():105753. PubMed ID: 37348363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation.
    Lemonnier J; Delannoy P; Hott M; Lomri A; Modrowski D; Marie PJ
    Exp Cell Res; 2000 Apr; 256(1):158-67. PubMed ID: 10739663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.
    Yu K; Herr AB; Waksman G; Ornitz DM
    Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14536-41. PubMed ID: 11121055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse.
    Wang Y; Xiao R; Yang F; Karim BO; Iacovelli AJ; Cai J; Lerner CP; Richtsmeier JT; Leszl JM; Hill CA; Yu K; Ornitz DM; Elisseeff J; Huso DL; Jabs EW
    Development; 2005 Aug; 132(15):3537-48. PubMed ID: 15975938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excessive osteoclast activation by osteoblast paracrine factor RANKL is a major cause of the abnormal long bone phenotype in Apert syndrome model mice.
    Shin HR; Kim BS; Kim HJ; Yoon H; Kim WJ; Choi JY; Ryoo HM
    J Cell Physiol; 2022 Apr; 237(4):2155-2168. PubMed ID: 35048384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of protein kinase Calpha, interleukin-1alpha, and RhoA guanosine 5'-triphosphatase in osteoblasts expressing the Ser252Trp fibroblast growth factor 2 receptor Apert mutation: identification by analysis of complementary DNA microarray.
    Lomri A; Lemonnier J; Delannoy P; Marie PJ
    J Bone Miner Res; 2001 Apr; 16(4):705-12. PubMed ID: 11315998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.